Opendata, web and dolomites

MultiDiag

Rapid, cost-effective, multiplex point of care diagnostic immunoassay system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MultiDiag project word cloud

Explore the words cloud of the MultiDiag project. It provides you a very rough idea of what is the project "MultiDiag" about.

made    panels    accuracy    central    care    platform    competition    array    patient    lined    first    commercialise    decades    multiplex    laboratory    diagnoses    intend    cartridge    mean    sensitive    biomarker    infectious    clinical    autoimmune    retaining    market    elisa    prepare    quantitative    globally    point    15    arrays    tested    oncology    perform    our    sensitivity    benefits    accurate    takes    disease    route    bench    modern    parallel    earliest    lt    plan    reduce    quantification    data    mainstay    handling    whilst    allergy    diagnostic    tests    biomarkers    feasibility    provides    device    standard    laboratories    series    rapid    cartridges    pricing    time    contrast    nalia    commercial    diseases    inherent    liquid    immunoassays    opportunity    business    hours    initial    incorporated    facilities    assesses    changed    diagnosis    near    20min    submit    stream    multiplexed    disposable    disorders    confirm    complete    manufacturable    accurately    followed    size    healthcare    dramatically   

Project "MultiDiag" data sheet

The following table provides information about the project.

Coordinator
NALIA SYSTEMS LIMITED 

Organization address
address: C/O DUBOFF & CO, KINGSBURY HOUSE, 468 CHURCH LANE
city: LONDON
postcode: NW9 8UA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.naliasystems.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NALIA SYSTEMS LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays. Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity. Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform. NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories. Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result. This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases. In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More